Cargando…

Pharmacokinetics and Biochemical Efficacy of an α(1)-Proteinase Inhibitor (Aralast NP) in α(1)-Antitrypsin Deficiency: a Cross-Product Retrospective Comparability Analysis

INTRODUCTION: Augmentation therapy with plasma-derived α(1)-proteinase inhibitor (A1PI) products is currently the only approved disease-specific therapy for α(1)-antitrypsin deficiency (AATD), a genetic disorder associated with decreased levels of A1PI. Systemic trough levels of A1PI in plasma or se...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Zhaoyang, Franke, Ryan M., Morris, Denise N., Yel, Leman
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9458804/ https://www.ncbi.nlm.nih.gov/pubmed/36001294 http://dx.doi.org/10.1007/s41030-022-00199-4

Ejemplares similares

A specific proteinase 3 activity footprint in α(1)-antitrypsin deficiency
por: Newby, Paul R., et al.
Publicado: (2019)

Quantitative disease progression model of α‐1 proteinase inhibitor therapy on computed tomography lung density in patients with α‐1 antitrypsin deficiency
por: Tortorici, Michael A., et al.
Publicado: (2017)

Update on α(1)-antitrypsin deficiency
por: Ferrarotti, Ilaria, et al.
Publicado: (2018)

Measurement of the α1-proteinase inhibitor (α1-antitrypsin) of common marmoset and intestinal protein loss in wasting syndrome
por: Niimi, Kimie, et al.
Publicado: (2019)

Appropriateness of Newborn Screening for α1-Antitrypsin Deficiency
por: Teckman, Jeffrey, et al.
Publicado: (2014)

Ruptured Gastric Aneurysm in α-1 Antitrypsin Deficiency
por: Jaruvongvanich, Veeravich, et al.
Publicado: (2016)

Molecular Mechanism of Z α1-Antitrypsin Deficiency
por: Huang, Xin, et al.
Publicado: (2016)

α(1)-Antitrypsin deficiency and chronic respiratory disorders
por: Cazzola, Mario, et al.
Publicado: (2020)

Stem cell-based therapy for α(1)-antitrypsin deficiency
por: Rashid, S Tamir, et al.
Publicado: (2012)

Deficiency of α-1-antitrypsin influences systemic iron homeostasis
por: Ghio, Andrew J, et al.
Publicado: (2013)

Flecainide and elevated liver enzymes in α1-antitrypsin deficiency
por: Jenkins, David J.A., et al.
Publicado: (2016)

COVID-19 vaccination in patients with α1-antitrypsin deficiency
por: Yang, Chengliang, et al.
Publicado: (2021)

The emerging role of proteases in α(1)-antitrypsin deficiency and beyond
por: Fazleen, Aishath, et al.
Publicado: (2021)

The effect of exacerbations on lung density in α(1)-antitrypsin deficiency
por: Strange, Charlie, et al.
Publicado: (2023)

The Course of AαVal541 as a Proteinase 3 Specific Neo-Epitope after Alpha-1-Antitrypsin Augmentation in Severe Deficient Patients
por: Schouten, Iris G. M., et al.
Publicado: (2021)

Alpha-1 proteinase inhibitors for the treatment of alpha-1 antitrypsin deficiency: safety, tolerability, and patient outcomes
por: Chotirmall, Sanjay H, et al.
Publicado: (2015)

Diagnosis and management of α(1)-antitrypsin deficiency in Europe: an expert survey
por: Horváth, Ildikó, et al.
Publicado: (2019)

Relationship Between α(1)-Antitrypsin Deficiency and Ascending Aortic Distention
por: Dako, Farouk, et al.
Publicado: (2021)

Diagnosing α(1)-antitrypsin deficiency: how to improve the current algorithm
por: McElvaney, Noel G.
Publicado: (2015)

α(1)-Antitrypsin deficiency associated with increased risk of heart failure
por: Winther, Sine V., et al.
Publicado: (2023)

Plasma levels of alpha1-antichymotrypsin and secretory leukocyte proteinase inhibitor in healthy and chronic obstructive pulmonary disease (COPD) subjects with and without severe α1-antitrypsin deficiency
por: Hollander, Camilla, et al.
Publicado: (2007)

α1-Antitrypsin deficiency and the risk of COVID-19: an urgent call to action
por: Yang, Chengliang, et al.
Publicado: (2021)

Lung microhaemorrhage drives oxidative/inflammatory damage in α(1)-antitrypsin deficiency
por: Saltini, Cesare, et al.
Publicado: (2023)

Diffuse panniculitis in a teenage male with ZZ α(1)-antitrypsin deficiency
por: Papiris, Spyros A., et al.
Publicado: (2023)

Arterivirus Papain-like Proteinase 1α
por: Nedialkova, Danny D., et al.
Publicado: (2013)

Augmentation therapy with human alpha-1-proteinase inhibitor reduces exacerbations in patient with bronchiectasis and alpha-1-antitrypsin deficiency
por: Buck, Emanuel, et al.
Publicado: (2022)

α(1)-Antitrypsin and the serpins: variation and countervariation
por: Carrell, Robin, et al.
Publicado: (1985)

Proteolysis and Deficiency of α1-Proteinase Inhibitor in SARS-CoV-2 Infection
por: Akbasheva, O. E., et al.
Publicado: (2022)

Deficient and Null Variants of SERPINA1 Are Proteotoxic in a Caenorhabditis elegans Model of α1-Antitrypsin Deficiency
por: Cummings, Erin E., et al.
Publicado: (2015)

Endotoxin receptor CD14 in PiZ α-1-antitrypsin deficiency individuals
por: Sandström, Caroline S, et al.
Publicado: (2008)

Targeted gene correction of α(1)-antitrypsin deficiency in induced pluripotent stem cells
por: Yusa, Kosuke, et al.
Publicado: (2011)

Matrix metalloproteinase-9 predicts pulmonary status declines in α(1)-antitrypsin deficiency
por: Omachi, Theodore A, et al.
Publicado: (2011)

The effects of weekly augmentation therapy in patients with PiZZ α1-antitrypsin deficiency
por: Schmid, ST, et al.
Publicado: (2012)

PReS-FINAL-2034: Α1 - Antitrypsin deficiency in children with arthritis: four cases
por: Pruunsild, C, et al.
Publicado: (2013)

Mysteries of α1-antitrypsin deficiency: emerging therapeutic strategies for a challenging disease
por: Ghouse, Raafe, et al.
Publicado: (2014)

Targeted screening programmes in COPD: how to identify individuals with α(1)-antitrypsin deficiency
por: Chorostowska-Wynimko, Joanna
Publicado: (2015)

Severe COVID-19 Illness and α1-Antitrypsin Deficiency: COVID-AATD Study
por: Rodríguez Hermosa, Juan Luis, et al.
Publicado: (2023)

Short-term variability of biomarkers of proteinase activity in patients with emphysema associated with type Z alpha-1-antitrypsin deficiency
por: Stolk, Jan, et al.
Publicado: (2005)

IS THERE A ROLE FOR α1-ANTITRYPSIN IN COVID-19?
por: Gurbel, Paul A., et al.
Publicado: (2021)

Steady-State Serum IgG Trough Levels Are Adequate for Pharmacokinetic Assessment in Patients with Immunodeficiencies Receiving Subcutaneous Immune Globulin
por: Li, Zhaoyang, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_lr0updji9foa9ool83vvt98054